

19 JANUARY 2021

LGP SIGNS EXCLUSIVE OILS DISTRIBUTION AGREEMENT WITH GERMAN DISTRIBUTOR AMP

ASX ANNOUNCEMENT

Highlights:

- ✔ LGP signs three-year distribution agreement with AMP for the distribution of LGP-branded cannabis oil medicines in Germany
- ✔ AMP is a leading pharmaceutical supplier of medical cannabis products with one of the largest medical liaison teams in Germany
- ✔ AMP agrees to purchase certain Minimum Annual Quantities and not promote any other cannabis oil products in Germany
- ✔ AMP granted exclusive rights to distribute two LGP-branded cannabis oils together with three other LGP-branded oils on a non-exclusive basis
- ✔ LGP may distribute and market its own LGP branded oils on its own behalf after the first year of the Agreement
- ✔ Agreement further strengthens distribution of LGP-branded oils into Germany and supports strong brand recognition of LGP products in Germany.

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce it has entered a three-year exclusive distribution agreement with AMP Medical Products GmbH (“AMP”) for the distribution of LGP cannabis oils in Germany.

Under the Agreement, AMP agrees to exclusively distribute and market LGP cannabis oil medicines and not promote any other oil products in Germany. In return, the Company will supply AMP with its 10:10 LGP Classic and 20:5 LGP Classic cannabis oils on an exclusive basis, as well as its 1:20 LGP Classic, 1:100 LGP Classic and CBD 50 LGP Classic oils on a non-exclusive basis.



AMP distribution and marketing capability

AMP is a leading pharmaceutical supplier of medical cannabis products, has one of the largest medical liaison teams in Germany, and hosts a broad range of well-attended medicinal cannabis education sessions for physicians and allied health professionals. The AMP Group is listed on stock exchanges in Germany and on the Canadian Securities Exchange.

Agreement drives LGP brand recognition in Germany

AMP represents a trusted and exclusive partner in Germany. LGP anticipates AMP's significant marketing and sales capability will help further grow patient and prescriber recognition of the LGP brand across its product suite.

Material terms of the Agreement

The Agreement is conditional upon AMP completing a supplier qualification into LGP, which LGP estimates will complete during Q2 (CY2022).

Under the Agreement, AMP must purchase Minimum Annual Quantities (**MAQ**) of at least 2,000 x 50ml units in the first year, 5,000 units in the second year and 10,000 units in the third year, provided that if LGP distributes LGP branded oils on its own account the quantities in the second and third years are reduced by 50%. AMP must ensure that at least 10% of the Minimum Annual Quantities purchased are non-exclusive oil products.

If AMP fails to purchase:

- the Minimum Quarterly Quantity for any two quarters during the Term LGP may cancel AMP's exclusivity;
- the MAQ in any year, LGP may terminate the Agreement with immediate effect; or
- the MAQ for year one, LGP may claim damages for any unpurchased MAQ quantities.

If there are any unsold products that have expired at the end of year one, LGP will be required to reimburse AMP with 50% of the amount paid for these products.

Under the Agreement LGP may also continue to sell white label oils through other distributors but will only sell the exclusive oil products through AMP in Germany.

ENDS



Alistair Warren
Company Secretary





For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 25 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp